A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- Insulin degludec/liraglutide
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Hefei,Hefei,Beijing,Beijing,Beijing,Beijing,ChongQing,Fuzhou,Guangzhou,Guangzhou,Hengshui,Shijiazhuang,Tangshan,Harbin,Yueyang,Huhehaote,Huhhot,Changzhou,Nanjing,Nanjing,Nanjing,Zhenjiang,Nanchang,Cha, China,China
- Phase
- Phase 3
- Start date
- May 26, 2017
- End date
- Apr 04, 2019
- Enrollment
- 453 participants
Change in HbA1c
This trial is conducted in Asia. The aim of this trial is to confirm the superiority of
 insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese
 subjects with type 2 diabetes mellitus after 26 weeks of treatment
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03175120
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT03175120 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 453 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.